Vycor Medical, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019
August 09, 2019 at 01:45 pm EDT
Share
Vycor Medical, Inc. announced earnings results for the second quarter ended June 30, 2019. For the second quarter, the company announced sales was USD 429,890 compared to USD 301,665 a year ago. Operating loss was USD 167,286 compared to USD 405,648 a year ago. Net loss was USD 185,304 compared to USD 418,584 a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.02 a year ago. For the half year, sales was USD 780,556 compared to USD 626,766 a year ago. Operating loss was USD 330,124 compared to USD 720,198 a year ago. Net loss was USD 365,602 compared to USD 745,220 a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.04 a year ago.
Vycor Medical, Inc. provides surgical and therapeutic solutions. The Company designs, develops and markets neurological medical devices and therapies. The Company operates through two segments: Vycor Medical and NovaVision. The Vycor Medical segment designs, develops and markets medical devices for use in neurosurgery. The NovaVision segment provides non-invasive rehabilitation therapies for those who have vision disorders resulting from neurological brain damage such as that caused by a stroke. Vycor Medical's product Vycor Medical's ViewSite Brain Access System (VBAS) is a next generation retraction and access system. Vycor Medical focuses on brain and cervical surgical access systems for sale to hospitals and medical professionals. NovaVision's products include Vision Restoration Therapy (VRT), NeuroEyeCoach and Neuro-Eye Therapy (NeEt). The Company operates in the United States and Europe.
VYCOR MEDICAL, INC. 
